Wednesday, 05 Nov 2025

STAT+: Novo Nordisk’s obesity drug Wegovy cleared to treat MASH

Written by
STAT News
Published
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago